Deirdre Nolfi-Donegan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Deirdre Nolfi-Donegan has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Gowtham K. Annarapu
Disease Biology Laboratory, Regional Centre for Biotechnology, National Capital Region Biotech Science Cluster, Faridabad, India
3 shared publications - Sruti Shiva
Vascular Medicine Institute, USA; Division of Classical Hematology, Department of Medicine, USA; Center for Metabolism and Mitochondrial Medicine, University of Pittsburgh School of Medicine, USA
3 shared publications James Cooper
Department of Pediatrics Division of Hematology/Oncology Children's Hospital of Pittsburgh Pittsburgh Pennsylvania USA
2 shared publications- Michael Reynolds
Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh School of Medicine–University of Pittsburgh Medical Center, Pittsburgh, PA
2 shared publications Yinna Wang
Pittsburgh Heart, Lung, Blood, Vascular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA
2 shared publications- Allison Close
Michigan State University College of Human Medicine Grand Rapids Michigan USA
1 shared publication
Latest Publications
- Open Access
- 12 February 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31589
Neonatal Portal Vein Thrombosis: A Retrospective Study of Management and Follow‐Up at One Institution
Background: Management of neonatal portal vein thrombosis (PVT), a relatively common type of pediatric deep vein thrombosis, is not completely standardized. Questions remain about the benefit of anticoagulation (ATC) therapy and about the optimal frequency and duration of doppler ultrasound (US) surveillance for liver complications such as portal hypertension and gastrointestinal bleeding. Current guidelines suggest reserving ATC only for occlusive PVT, highlighting a need for explicit grading of PVT in radiologic reports and a consensus approach to imaging and management. Methods: To address these issues, we implemented an institutional Neonatal PVT Management Algorithm using plan–do–study–act (PDSA) methodology. We aimed to standardize screening tests, reduce unnecessary ATC, and optimize imaging checkpoints. A five‐year retrospective review established baseline data, which we compared to outcomes five years post‐implementation of the algorithm. Results: The algorithm recommended ATC only for occlusive PVT and advised US imaging at Week 1, Month 1, Month 3, and Month 6 from diagnosis, with annual surveillance for unresolved or abnormal cases. Post‐implementation analysis revealed improvements in radiologic documentation of PVT grading, a reduction in the use of ATC for subocclusive PVT, and a decrease in the median duration of ATC for all patients. Follow‐up imaging adherence did not improve between the pre‐ and post‐implementation periods. Conclusions: The algorithm successfully enhanced documentation of PVT grading and reduced unnecessary ATC but highlighted persistent challenges in follow‐up adherence, suggesting a need for further refinement in future PDSA cycles.
- 12 February 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (5) , e31589
Open AccessNeonatal Portal Vein Thrombosis: A Retrospective Study of Management and Follow‐Up at One Institution
Background: Management of neonatal portal vein thrombosis (PVT), a relatively common type of pediatric deep vein thrombosis, is not completely standardized. Questions remain about the benefit of anticoagulation (ATC) therapy and about the optimal frequency and duration of doppler ultrasound (US) surveillance for liver complications such as portal hypertension and gastrointestinal bleeding. Current guidelines suggest reserving ATC only for occlusive PVT, highlighting a need for explicit grading of PVT in radiologic reports and a consensus approach to imaging and management. Methods: To address these issues, we implemented an institutional Neonatal PVT Management Algorithm using plan–do–study–act (PDSA) methodology. We aimed to standardize screening tests, reduce unnecessary ATC, and optimize imaging checkpoints. A five‐year retrospective review established baseline data, which we compared to outcomes five years post‐implementation of the algorithm. Results: The algorithm recommended ATC only for occlusive PVT and advised US imaging at Week 1, Month 1, Month 3, and Month 6 from diagnosis, with annual surveillance for unresolved or abnormal cases. Post‐implementation analysis revealed improvements in radiologic documentation of PVT grading, a reduction in the use of ATC for subocclusive PVT, and a decrease in the median duration of ATC for all patients. Follow‐up imaging adherence did not improve between the pre‐ and post‐implementation periods. Conclusions: The algorithm successfully enhanced documentation of PVT grading and reduced unnecessary ATC but highlighted persistent challenges in follow‐up adherence, suggesting a need for further refinement in future PDSA cycles.
- Open Access
- 23 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (5)
High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease
Thrombosis and inflammation are intimately linked and synergistically contribute to the pathogenesis of numerous thromboinflammatory diseases, including sickle cell disease (SCD). While platelets are central to thrombogenesis and inflammation, the molecular mechanisms of crosstalk between the 2 remain elusive. High-mobility group box 1 (HMGB1) regulates inflammation and stimulates platelet activation through Toll-like receptor 4. However, it remains unclear whether HMGB1 modulates other thrombotic agonists to regulate platelet activation. Herein, using human platelets, we demonstrate that HMGB1 significantly enhanced ADP-mediated platelet activation. Furthermore, inhibition of the purinergic receptor P2Y 12 attenuated HMGB1-dependent platelet activation. Mechanistically, we show that HMGB1 stimulated ADP secretion, while concomitantly increasing P2Y 12 levels at the platelet membrane. We show that in SCD patients, increased plasma HMGB1 levels were associated with heightened platelet activation and surface P2Y 12 expression. Treatment of healthy platelets with plasma from SCD patients enhanced platelet activation and surface P2Y 12 , and increased sensitivity to ADP-mediated activation, and these effects were linked to plasma HMGB1. We conclude that HMGB1-mediated platelet activation involves ADP-dependent P2Y 12 signaling, and HMGB1 primes platelets for ADP signaling. This complementary agonism between ADP and HMGB1 furthers the understanding of thromboinflammatory signaling in conditions such as SCD, and provides insight for therapeutic P2Y 12 inhibition.
- 23 January 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (5)
Open AccessHigh-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease
Thrombosis and inflammation are intimately linked and synergistically contribute to the pathogenesis of numerous thromboinflammatory diseases, including sickle cell disease (SCD). While platelets are central to thrombogenesis and inflammation, the molecular mechanisms of crosstalk between the 2 remain elusive. High-mobility group box 1 (HMGB1) regulates inflammation and stimulates platelet activation through Toll-like receptor 4. However, it remains unclear whether HMGB1 modulates other thrombotic agonists to regulate platelet activation. Herein, using human platelets, we demonstrate that HMGB1 significantly enhanced ADP-mediated platelet activation. Furthermore, inhibition of the purinergic receptor P2Y 12 attenuated HMGB1-dependent platelet activation. Mechanistically, we show that HMGB1 stimulated ADP secretion, while concomitantly increasing P2Y 12 levels at the platelet membrane. We show that in SCD patients, increased plasma HMGB1 levels were associated with heightened platelet activation and surface P2Y 12 expression. Treatment of healthy platelets with plasma from SCD patients enhanced platelet activation and surface P2Y 12 , and increased sensitivity to ADP-mediated activation, and these effects were linked to plasma HMGB1. We conclude that HMGB1-mediated platelet activation involves ADP-dependent P2Y 12 signaling, and HMGB1 primes platelets for ADP signaling. This complementary agonism between ADP and HMGB1 furthers the understanding of thromboinflammatory signaling in conditions such as SCD, and provides insight for therapeutic P2Y 12 inhibition.
- Open Access
- 5 December 2021
- Published by Elsevier in Redox Biology
- Vol. 48, 102205
Heme stimulates platelet mitochondrial oxidant production to induce targeted granule secretion
- 5 December 2021
- Published by Elsevier in Redox Biology
- Vol. 48, 102205
Open AccessHeme stimulates platelet mitochondrial oxidant production to induce targeted granule secretion
- Open Access
- 8 October 2021
- Published by Wiley in American Journal of Hematology
- Vol. 96 (12) , 1708-1714
Splenic kaposiform hemangioendothelioma presenting as insidious consumptive coagulopathy
- 8 October 2021
- Published by Wiley in American Journal of Hematology
- Vol. 96 (12) , 1708-1714
Open AccessSplenic kaposiform hemangioendothelioma presenting as insidious consumptive coagulopathy
- 16 March 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 19 (9) , 2256-2262
Mitochondrial reactive oxygen species scavenging attenuates thrombus formation in a murine model of sickle cell disease
- 16 March 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 19 (9) , 2256-2262
Mitochondrial reactive oxygen species scavenging attenuates thrombus formation in a murine model of sickle cell disease
- Open Access
- 1 August 2018
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 24 (8) , 1561-1564
Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab
Patients receiving eculizumab have an increased risk for meningococcal disease, but most reported cases are attributable to encapsulated meningococcal strains. We describe a case in which a nongroupable meningococcal strain, which rarely causes disease in healthy persons, caused fatal disease in an eculizumab recipient despite meningococcal vaccination.
- 1 August 2018
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 24 (8) , 1561-1564
Open AccessFatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab
Patients receiving eculizumab have an increased risk for meningococcal disease, but most reported cases are attributable to encapsulated meningococcal strains. We describe a case in which a nongroupable meningococcal strain, which rarely causes disease in healthy persons, caused fatal disease in an eculizumab recipient despite meningococcal vaccination.